| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.2 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.052 | 0.2 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 0.2 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | 0.055 | 0.2 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.2 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.2 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.12 | 0.2 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.087 | 0.2 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | 0.077 | 0.2 |